Morgan Stanley
CMRA

Morgan Stanley’s Comera Life Sciences Holdings, Inc. Common Stock CMRA Stock Holding History

Morgan Stanley’s Portfolio CMRA Stock Details CMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-2,292
Closed -$668 – 7996
2023
Q3 		$668 Hold
2,292
– – ﹤0.01% 7276
2023
Q2 		$1.12K Hold
2,292
– – ﹤0.01% 7280
2023
Q1 		$2.06K Sell
2,292
-3
-0.1% -$4 ﹤0.01% 7230
2022
Q4 		$2.82K Buy
2,295
+1
+0% +$1 ﹤0.01% 7289
2022
Q3 		$4K Buy
2,294
+2
+0.1% +$5 ﹤0.01% 7345
2022
Q2 		$6K Buy
+2,292
New +$7.59K ﹤0.01% 7375

Morgan Stanley's CMRA Position: Q4 2023 in Review

Morgan Stanley sold out of Comera Life Sciences Holdings, Inc. Common Stock (CMRA) in Q4 2023, closing a stake of 2,292 shares — an estimated $668 sold.

Morgan Stanley first reported a position in CMRA in Q2 2022 and held it in 6 quarters. The position peaked at $6K in Q2 2022. 0 funds tracked by Wall St. Rank hold CMRA as of Q4 2023.

  • Morgan Stanley reported no remaining Comera Life Sciences Holdings, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Morgan Stanley sold 2,292 Comera Life Sciences Holdings, Inc. Common Stock shares in Q4 2023, an estimated $668.
  • Morgan Stanley first reported a position in Comera Life Sciences Holdings, Inc. Common Stock in Q2 2022 and held it in 6 quarters.
  • Morgan Stanley's Comera Life Sciences Holdings, Inc. Common Stock position peaked at $6K in Q2 2022.
  • 0 funds tracked by Wall St. Rank held Comera Life Sciences Holdings, Inc. Common Stock as of Q4 2023.

Based on Morgan Stanley's 13F filing for Q4 2023, filed 13 Feb 2024.